NICE National Institute for Health and Care Excellence

NICE guidance

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal)

Technology appraisal guidance
Published: 14 August 2019

www.nice.org.uk/guidance/ta594

Contents

Advice

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin for untreated advanced Hodgkin lymphoma because Takeda did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal because it considers that, at this time, there is insufficient evidence to provide a UK submission for this appraisal. The company has confirmed that it does not intend to make a submission for the appraisal until data from a key study in this indication are available in June 2021.

Information

If NHS organisations wish to consider brentuximab vedotin, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-3488-1

Accreditation